Literature DB >> 17454716

Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Benjamin A Toll1, Sherry A McKee, Daniel J Martin, Peter Jatlow, Stephanie S O'Malley.   

Abstract

The Medication Adherence Questionnaire (MAQ) is a scale used to evaluate adherence to medications. The present study assessed the factor structure and validity of the MAQ with cigarette smokers. A principal components analysis was conducted on MAQ scores from a sample of smokers presenting for treatment in a clinical trial of naltrexone and nicotine patch for smoking cessation (N = 385). Indices of convergent and predictive validity were tested using electronic medication caps for naltrexone, nicotine patch counts, plasma drug levels of naltrexone, and treatment outcomes. The principal components analysis revealed two factors. Factor 1, labeled "unintentional nonadherence," measured the extent to which individuals were nonadherent because they were careless or forgot to take their medications. Factor 2, labeled "purposeful nonadherence," assessed nonadherence related to purposefully stopping medication use after feeling better or worse. Only the second factor was shown to have good convergent and predictive validity. Specifically, this factor was related to pill-taking behavior measured with electronic medication caps and drug plasma levels and nicotine patch use based on nicotine patch count data, and it was associated with smoking cessation outcome. Thus the purposeful nonadherence factor of the MAQ may be used as a brief screening tool for medication adherence with cigarette smokers seeking treatment. Information obtained with this questionnaire could be used to counsel patients regarding the importance of medication adherence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454716      PMCID: PMC2527736          DOI: 10.1080/14622200701239662

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  44 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Correlates of adherence with transdermal nicotine.

Authors:  Theodore V Cooper; Margaret W DeBon; Michelle Stockton; Robert C Klesges; Timothy A Steenbergh; Deborah Sherrill-Mittleman; Lyndy C Jennings; Karen C Johnson
Journal:  Addict Behav       Date:  2004-11       Impact factor: 3.913

3.  Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at 'real-world' patch users.

Authors:  C T Orleans; N Resch; E Noll; M K Keintz; B K Rimer; T V Brown; T M Snedden
Journal:  JAMA       Date:  1994-02-23       Impact factor: 56.272

4.  Factors associated with medication nonadherence in patients with COPD.

Authors:  Johnson George; David C M Kong; Rambha Thoman; Kay Stewart
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

5.  Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study.

Authors:  F Venturini; M B Nichol; J C Sung; K L Bailey; M Cody; J S McCombs
Journal:  Ann Pharmacother       Date:  1999-03       Impact factor: 3.154

6.  Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice.

Authors:  R J Pratt; N Robinson; H P Loveday; C M Pellowe; P J Franks; M Hankins; C Loveday
Journal:  HIV Clin Trials       Date:  2001 Mar-Apr

7.  Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.

Authors:  Hernando Knobel; Jordi Alonso; José L Casado; Julio Collazos; Juan González; Isabel Ruiz; José M Kindelan; Alexia Carmona; Javier Juega; Antonio Ocampo
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

8.  Bupropion for smoking cessation : predictors of successful outcome.

Authors:  L C Dale; E D Glover; D P Sachs; D R Schroeder; K P Offord; I T Croghan; R D Hurt
Journal:  Chest       Date:  2001-05       Impact factor: 9.410

9.  Medication adherence and associated hemoglobin A1c in type 2 diabetes.

Authors:  Kimberley Krapek; Kathleen King; Susan S Warren; Karen G George; Dorothy A Caputo; Karen Mihelich; Elizabeth M Holst; Michael B Nichol; Sheng G Shi; Kevin B Livengood; Steve Walden; Teresa J Lubowski
Journal:  Ann Pharmacother       Date:  2004-07-06       Impact factor: 3.154

10.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Authors:  Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

View more
  29 in total

1.  Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report.

Authors:  Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen
Journal:  Nicotine Tob Res       Date:  2012-02-24       Impact factor: 4.244

2.  Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.

Authors:  Ralitza Gueorguieva; Ran Wu; John H Krystal; Dennis Donovan; Stephanie S O'Malley
Journal:  Addict Behav       Date:  2013-02-04       Impact factor: 3.913

Review 3.  What are validated self-report adherence scales really measuring?: a systematic review.

Authors:  Thi-My-Uyen Nguyen; Adam La Caze; Neil Cottrell
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

4.  Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.

Authors:  Kelly E Dunn; Taylor F Marcus; Cynthia Kim; Jennifer R Schroeder; Ryan Vandrey; Annie Umbricht
Journal:  Nicotine Tob Res       Date:  2015-10-17       Impact factor: 4.244

5.  Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants.

Authors:  Hadi Beyhaghi; Bryce B Reeve; Jo E Rodgers; Sally C Stearns
Journal:  Value Health       Date:  2016-08-31       Impact factor: 5.725

6.  Co-occurring marijuana use is associated with medication nonadherence and nonplanning impulsivity in young adult heavy drinkers.

Authors:  Erica N Peters; Robert F Leeman; Lisa M Fucito; Benjamin A Toll; William R Corbin; Stephanie S O'Malley
Journal:  Addict Behav       Date:  2011-12-03       Impact factor: 3.913

7.  Adherence to varenicline in the COMPASS smoking cessation intervention trial.

Authors:  Sheryl L Catz; Lisa M Jack; Jennifer B McClure; Harold S Javitz; Mona Deprey; Susan M Zbikowski; Tim McAfee; Julie Richards; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2011-02-24       Impact factor: 4.244

8.  The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial.

Authors:  A Zweben; M E Piepmeier; L Fucito; S S O'Malley
Journal:  J Subst Abuse Treat       Date:  2017-04-04

Review 9.  Opioid antagonists for smoking cessation.

Authors:  Sean P David; Tim Lancaster; Lindsay F Stead; A Eden Evins; Judith J Prochaska
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

10.  Lessons learned in the development and evaluation of RxCoach™, an mHealth app to increase tobacco cessation medication adherence.

Authors:  Judith S Gordon; Julie S Armin; James K Cunningham; Myra L Muramoto; Steven M Christiansen; Thomas A Jacobs
Journal:  Patient Educ Couns       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.